Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $205,964.00 in Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $14.92 on Friday. The firm has a market capitalization of $1.27 billion, a PE ratio of -4.11 and a beta of 0.90. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.06 and a 1-year high of $25.34. The company’s fifty day moving average price is $13.88 and its 200-day moving average price is $17.19.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. grew its holdings in shares of Syndax Pharmaceuticals by 62.5% during the third quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock valued at $2,352,000 after buying an additional 46,992 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after purchasing an additional 208,043 shares during the last quarter. State Street Corp boosted its holdings in Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock valued at $72,588,000 after purchasing an additional 148,491 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Syndax Pharmaceuticals by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock valued at $13,397,000 after purchasing an additional 41,458 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Syndax Pharmaceuticals by 143.4% in the third quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after purchasing an additional 110,535 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages recently commented on SNDX. Citigroup boosted their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 19th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group lifted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).